The drug maker announced Monday night that the 60,000-patient, late-stage trials have been put on hold and new enrollment has been halted, citing “an unexplained illness in a study participant.”
from MarketWatch.com - Top Stories https://ift.tt/3jOBfoa
No comments:
Post a Comment